Bridging the Gap: Addressing Disparities in GVHD Care
ASTCT Talks
by ASTCT
2w ago
In this episode of ASTCT Talks, host Dr. Andrés Gómez De León is joined by Dr. Nandita Khera and Dr. Alexandra Gomez Arteaga to explore the critical issue of disparities and barriers to care in graft-versus-host disease (GVHD). The discussion delves into the factors contributing to unequal access to hematopoietic cell transplantation, such as socioeconomic status, race, and ethnicity, both in the U.S. and globally. The guests highlight initiatives like the ACCESS Initiative by ASTCT and the National Marrow Donor Program, aimed at addressing these disparities through advocacy, awareness, and tr ..read more
Visit website
Managing Secondary Cancer Risks After CAR T-Cell Therapy in Multiple Myeloma Subgroups
ASTCT Talks
by ASTCT
1M ago
In a special co-branded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)’s program ASTCT Talks, Rahul Banerjee, MD, FACP, and Noopur Raje, MD, discussed the risk of secondary malignancies in patients with multiple myeloma who receive CAR T-cell therapy. Banerjee is an assistant professor in the Clinical Research Division of Fred Hutchinson Cancer Center and an assistant professor in the Division of Hematology and Oncology at the University of Washington. Raje is the director of the Center for Multiple Myeloma at Massac ..read more
Visit website
Exploring Insights From CAR-TITUDE 4 and KarMMa-3 Trials with Dr. Jens Hillengass
ASTCT Talks
by ASTCT
1M ago
In this episode of ASTCT Talks, Dr. Muhammad Salman Faisal is joined by Dr. Jens Hillengass. Dr. Hillengass discusses the latest advancements in CAR T cell therapy, focusing on its application in early-line settings following the results of the CAR-TITUDE 4 and KarMMa-3 trials. Tune in as he shares insights on the efficacy, patient selection and future directions of CAR-T cell therapy in multiple myeloma. This episode is supported by Johnson & Johnson and Legend Biotech. Don’t miss out on this informative discussion with one of the leading experts in the field. About Dr. Jens Hillengass Je ..read more
Visit website
Exploring Insights from CAR-TITUDE 4 and KarMMa-3 Trials with Dr. Jens Hillengass
ASTCT Talks
by ASTCT
2M ago
In this episode of ASTCT Talks, Dr. Muhammad Salman Faisal is joined by Dr. Jens Hillengass. Dr. Hillengass discusses the latest advancements in CAR T cell therapy, focusing on its application in early-line settings following the results of the CAR-TITUDE 4 and KarMMa-3 trials. Tune in as he shares insights on the efficacy, patient selection and future directions of CAR-T cell therapy in multiple myeloma. This episode is supported by Johnson & Johnson. Don’t miss out on this informative discussion with one of the leading experts in the field. About Dr. Jens Hillengass Jens Hillengass, MD ..read more
Visit website
A New Era in GVHD Prophylaxis: A Conversation With Dr. Samer Al-Homsi
ASTCT Talks
by ASTCT
3M ago
In this episode of "ASTCT Talks," Dr. Shernan Holtan sits down with Dr. Samer Al-Homsi, as he shares his insights on the future of graft versus host disease (GVHD) prophylaxis, particularly in haploidentical transplantation. Dr. Al-Homsi delves into the innovative CAST regimen, which combines post-transplant cyclophosphamide, abatacept and short-duration tacrolimus. Learn about the challenges, breakthroughs and promising results that could revolutionize how we approach GVHD prevention and treatment, making a future without GVHD a reality. Listen in as we explore the potential for reducing tran ..read more
Visit website
Beyond Remission: Navigating the Late Effects of Pediatric CAR T-Cell Therapy
ASTCT Talks
by ASTCT
5M ago
In this episode "ASTCT Talks,” hosts Rebecca Epperly, MD, and Aimee Talleur, MD, from St. Jude Children's Research Hospital, dive into the pioneering realm of CAR T-cell therapy and its late effects on pediatric patients. The discussion unfolds at the intersection of innovation and caution, highlighting the recent sessions from the 2024 Tandem meetings. They explore the emerging challenges and lack of data concerning long-term impacts of this revolutionary treatment, particularly in pediatric, adolescent, and young adult populations. This episode sheds light on both the immense potential and t ..read more
Visit website
A Conversation with Mike Niles: Author of ‘Hard Graft: Our Fight Against Killer Blood’
ASTCT Talks
by ASTCT
8M ago
In this latest episode of ASTCT Talks, Rachel Schollmeier and NMDP’s Samantha Watters host author Mike Niles, delving into the captivating history of the Anthony Nolan bone marrow transplant register. Explore the evolution of transplantation, from no donor registries to international initiatives, and gain a deeper understanding of the challenges faced by bone marrow registries today. Discover the inspiring narratives behind bone marrow donation and the transformative advancements that continue to shape the future of transplantation. Plus, don't miss the chance to connect with Samantha's podcas ..read more
Visit website
Titans of Transplant: Dr. Stephanie Lee
ASTCT Talks
by ASTCT
9M ago
In the next installment of ASTCT’s Titans of Transplant series, Dr. Stephanie Lee is interviewed by Dr. Jennifer Saultz. Dr. Lee shares her journey from Seattle to becoming a professor at Fred Hutch Cancer Center. The conversation highlights early motivations, challenges faced during fellowship, and the influence of her father's advice to always strive for the best. They also discuss Dr. Lee's groundbreaking work in chronic graft-versus-host-disease research, collaborative efforts, FDA-approved treatments, and the evolving landscape in the field. The Titans of Transplant series seeks to recogn ..read more
Visit website
Navigating CAR-T Survivorship
ASTCT Talks
by ASTCT
11M ago
In this latest episode of ASTCT Talks, Cory M. Edgar, DMSc, PA-C, sits down with Sarah Fitzmaurice, APRN, where they delve into the evolving landscape of survivorship care, particularly in the realm of CAR T-cell therapy. They discuss the development of CAR T-specific protocols, emphasizing the importance of post-treatment monitoring and patient education. They also explore the challenges of defining survivorship, the multidisciplinary nature of care, and insights into late effects, deconditioning, cognitive changes, and psychological concerns beyond the first year. Tune into this episode of ..read more
Visit website
Beyond BCMA: Exploring Talquetamab in Myeloma Therapy
ASTCT Talks
by ASTCT
11M ago
In this latest episode of ASTCT Talks, Dr. Rahul Banerjee, MD, FACP, sits down with Dr. Amrita Krishnan, MD. They delve into the use of GPRC5D as a target in myeloma therapy, specifically focusing on Talquetamab. Dr. Krishnan shares insights from the MonumenTAL-1 trial, discussing the dosing schedules and response rates with GPRC5D-targeted therapy. They explore the unique toxicities associated with this treatment, such as cytokine release syndrome and skin and nail toxicities. The conversation also touches on the considerations for patients who have previously received BCMA-targeted therapie ..read more
Visit website

Follow ASTCT Talks on FeedSpot

Continue with Google
Continue with Apple
OR